CG223 + CG250

CG223 and CG250 are first-in-class, oral, small molecule dual inhibitors developed by ConverGene as part of the CVG101 development program. These lead candidates exhibit a unique dual mechanism of action by simultaneously targeting Bromodomain and Extra-Terminal (BET) proteins and Dopamine Receptor 2 (DRD2). This approach is designed to suppress the MYC oncogene through BET inhibition while concurrently blocking DRD2 signaling, which is frequently upregulated in various cancers. By inhibiting these two distinct pathways, the compounds aim to suppress cell proliferation and induce apoptosis in both solid and liquid tumors. Currently in preclinical development, these candidates are being evaluated for indications including solid tumors and Acute Myelogenous Leukemia (AML), with a focus on maintaining an excellent safety profile while achieving potent anti-cancer activity.